Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment

Phase 3CompletedNCT02055118

Shire58 enrolled

Overview

Study HGT-HIT-094 is a multicenter study designed to determine the effect on clinical parameters of neurodevelopmental status of monthly IT administration of idursulfase-IT 10 mg for 12 months in pediatric patients with Hunter syndrome and cognitive impairment who have previously received and tolerated a minimum of 4 months of therapy with Elaprase.

Elaprase, a large molecular protein, is not expected to cross the blood brain barrier when administered intravenously. A revised formulation of idursulfase, idursulfase-IT, that differs from that of the intravenous (IV) formulation, Elaprase, has been developed to be suitable for delivery into the cerebrospinal fluid (CSF) via intrathecal administration. Mucopolysaccharidosis II (MPS II) is a rare, X-linked, inherited disease that affects males nearly exclusively. The disease is caused by the absence of, or deficiency in, the activity of the lysosomal enzyme, iduronate-2-sulfatase (I2S) which acts to cleave O-linked sulfate moieties from the glycosaminoglycan (GAG) molecules dermatan sulfate and heparan sulfate. Study HGT-HIT-094 is a controlled, randomized, two-arm, open-label, assessor-blinded, multicenter study to determine the effect on clinical parameters of neurodevelopmental status of monthly IT administration of idursulfase-IT 10 mg for 12 months in pediatric patients with Hunter syndrome and cognitive impairment who have previously received and tolerated a minimum of 4 months of therapy with Elaprase. Pediatric patients under 3 years of age will be enrolled into a separate substudy to evaluate the safety and efficacy of idursulfase-IT. The separate substudy is open label and single arm. Patients who are enrolled in the substudy will receive idursulfase-IT treatment and follow the same schedule of study visits.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Hunter Syndrome

Interventions

idursulfase-ITBIOLOGICAL

10mg

No IT treatmentOTHER

Standard of Care

Eligibility

Sex: MALEMax age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria Inclusion Criteria for the Pivotal Study Patients must meet all of the following criteria to be considered eligible for randomization in the pivotal study: 1. The patient is male and is ≥3 and \<18 years of age at the time of informed consent. (Patients who are younger than 3 years of age may be enrolled in a separate substudy provided that they meet other inclusion criteria, provided below.) 2. The patient must have a documented diagnosis of MPS II. 3. The patient has evidence at Screening of Hunter syndrome-related cognitive impairment defined as follows: A patient who is ≥3 and \<13 years of age must have one of the following criteria (3a OR 3b): 1. A GCA score ≥55 and ≤85 OR 2. If the patient has a GCA score at Screening \>85, there must be evidence of a decrease in GCA score of ≥10 points over 12 months from a previously documented test result in observational study HGT-HIT-090. A patient who is ≥13 and \<18 years of age must have both of the following criteria (3c AND 3d): 3. A GCA score of ≥55 and ≤85. AND 4. There must be evidence of a decrease in GCA score of ≥10 points over 12 months from a previously documented 4. The patient has received and tolerated a minimum of 4 months of therapy with Elaprase during the period immediately prior to Screening. 5. The patient must have sufficient auditory capacity, with a hearing aid(s), if needed, in the Investigator's judgment to complete the required protocol testing and must be compliant with wearing the hearing aid(s), if needed, on scheduled testing days. 6. The patient's parent(s) or legally authorized guardian(s) must have voluntarily signed an Institutional Review Board/Independent Ethics Committee approved informed consent form after all relevant aspects of the study have been explained and discussed. Consent of the patient's parent(s) or legally authorized guardian(s) and the patient's assent, if applicable, must be obtained prior to the start of any study procedures. Inclusion Criteria for the Substudy Patients must meet all of the following criteria to be considered eligible for enrollment in the separate substudy: 1. The patient is male and is \<3 years of age at the time of informed consent. 2. The patient must have a documented diagnosis of MPS II. 3. The patient has evidence at Screening of Hunter syndrome-related cognitive impairment 4. The patient has received and tolerated a minimum of 4 months of therapy with Elaprase during the period immediately prior to Screening. 5. The patient must have sufficient auditory capacity, with a hearing aid(s), if needed, in the Investigator's judgment to complete the required protocol testing and must be compliant with wearing the hearing aid(s), if needed, on scheduled testing days. 6. The patient's parent(s) or legally authorized guardian(s) must have voluntarily signed an Institutional Review Board/Independent Ethics Committee approved informed consent form after all relevant aspects of the study have been explained and discussed. Consent of the patient's parent(s) or legally authorized guardian(s) must be obtained prior to the start of any study procedures. Exclusion Criteria Patients who meet any of the following criteria are not eligible to be randomized into the pivotal study or enrolled in the separate substudy: 1. The patient has clinically significant non-Hunter syndrome-related CNS involvement (such as Fragile-X syndrome) which is judged by the Investigator to be likely to interfere with the accurate administration and interpretation of protocol assessments. 2. The patient has a large chromosomal deletion or complex rearrangement that includes a deletion of the FMR1 and/or FMR2 genes. 3. The patient has a significant medical or psychiatric comorbidity(ies) that might affect study data or confound the integrity of study results. 4. The patient has contra-indications for performance of lumbar puncture such as musculoskeletal/spinal abnormalities or risk of abnormal bleeding. 5. The patient has a history of complications from previous lumbar punctures or technical challenges in conducting lumbar punctures such that the potential risks would exceed possible benefits for the patient. 6. The patient has an opening CSF pressure upon lumbar puncture that exceeds 30.0 cm H2O. 7. The patient has experienced infusion-related anaphylactoid event(s) or has evidence of consistent severe adverse events related to treatment with Elaprase which, in the Investigator's opinion, may pose an unnecessary risk to the patient. 8. The patient has received a cord blood or bone marrow transplant at any time or has received blood product transfusions within 90 days prior to Screening. 9. The patient has a history of poorly controlled seizure disorder. 10. The patient is unable to comply with the protocol (eg, has significant hearing or vision impairment, a clinically relevant medical condition making implementation of the protocol difficult, unstable social situation, known clinically significant psychiatric/behavioral instability, is unable to return for safety evaluations, or is otherwise unlikely to complete the study), as determined by the Investigator. 11. The patient is enrolled in another clinical study that involves clinical investigation or use of any investigational product (drug or \[intrathecal/spinal\] device) within 30 days prior to study enrollment or at any time during the study. 12. The patient has any known or suspected hypersensitivity to anesthesia or is thought to be at an unacceptably high risk for anesthesia due to compromised airways or other conditions. 13. The patient has a condition that is contraindicated as described in the SOPH-A-PORT Mini S IDDD Instructions for Use (IFU), including but not limited to the presence of a CSF shunt device in the patient.

Locations (9)

Children's Hospital and Research Center at Oakland

Oakland, California, United States

Ann & Robert H Lurie Children's Hospital of Chicago

Chicago, Illinois, United States

University of North Carolina

Chapel Hill, North Carolina, United States

Outcomes

Primary Outcomes

Change From Baseline in the Differential Ability Scales, Second Edition (DAS-II) General Conceptual Ability (GCA) Standard Score at Week 52

The DAS-II was used to assess cognitive development in all randomized participants. The GCA standard score of the DAS-II was used to obtain a general measure of cognitive ability. The GCA score represent a score (mean = 100 and standard deviation of 15) on which higher scores indicate a higher level of cognitive ability. The score ranges from 30 to 170. A positive change value indicates improvement in cognitive ability.

Time frame: Baseline, Week 52

Secondary Outcomes

Change From Baseline in the Vineland Adaptive Behavior Scales, Second Edition (VABS-II) Adaptive Behavior Composite (ABC) Score at Week 52

The VABS-II test measures adaptive behaviors, including the ability to cope with environmental changes, to learn new everyday skills, and to demonstrate independence. This test measures the following 4 key domains: communication, daily living skills, socialization, motor skills, and the adaptive behavior composite (a composite of the other 4 domains). The ABC score ranges from 20 to 160 on which higher scores indicate a higher level of adaptive functioning. A positive change value indicates improvement in adaptive functioning.

Time frame: Baseline, Week 52

Change From Baseline in the Differential Ability Scales, Second Edition (DAS-II) General Conceptual Ability (GCA) Standard Score at Weeks 16, 28 and 40

Time frame: Baseline, Week 16, Week 28 and Week 40

Change From Baseline in the Vineland Adaptive Behavior Scales, Second Edition (VABS-II) Adaptive Behavior Composite (ABC) Score at Week 16, 28 and 40

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Women's and Children's Hospital, 72 King William Road

North Adelaide, Australia

The Hospital for Sick Children

Toronto, Ontario, Canada

Hôpital Femme Mère Enfant

Bron, France

Instituto Nacional de Pediatría

Coyoacán, Mexico City, Mexico

Hospital Infantil Universitario Niño Jesus

Madrid, Spain

Royal Manchester Children's Hospital

Manchester, United Kingdom

Time frame: Baseline, Week 16, Week 28 and Week 40

Change From Baseline in Differential Ability Scales, Second Edition (DAS-II) Cluster Standard Scores at Weeks 16, 28, 40 and 52

The DAS-II was used to assess cognitive development in all randomized participants. The cluster scores represent a score (mean = 100 and standard deviation of 15) on which higher scores indicate a higher level of cognitive ability in each cluster: verbal (score range: 31-169), nonverbal (score range: 31-166) and spatial (score range: 32-170).